Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Liu, Rong Pei ^a   Zou, Ming ^a   Wang, Jian Yong ^a   Zhu, Juan Juan ^a   Lai, Jun Mei ^a   Zhou, Li Li ^a   Chen, Song Fang ^a   Zhang, Xiong ^a   Zhu, Jian Hong ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Lipopolysaccharide; MAPK; Microglia; Neuroinflammation; Paroxetine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOKINE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PAROXETINE; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; SEROTONIN UPTAKE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME REPRESSION; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROGLIA; MICROGLIA ACTIVATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTINEUROINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DEPRESSION; DISEASE COURSE; DRUG ACTIVITY; ENZYME ACTIVITY;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CULTURE MEDIA, CONDITIONED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED ICR; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRIC OXIDE SYNTHASE TYPE II; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84899135670     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-47     Document Type: Article

References (46)

1. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):S3-S7.
2. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69. 10.1038/nrn2038, 17180163.
3. Appel SH. Inflammation in Parkinson's disease: cause or consequence?. Mov Disord 2012, 27:1075-1077. 10.1002/mds.25111, 22806694.
4. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010, 129:154-169. 10.1111/j.1365-2567.2009.03225.x, 2814458, 20561356.
5. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009, 68:217-226. 10.1097/NEN.0b013e3181996688, 19225414.
6. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59. 10.1016/j.cell.2009.01.038, 2754279, 19345186.
7. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934. 10.1016/j.cell.2010.02.016, 2873093, 20303880.
8. Hsieh PF, Chia LG, Ni DR, Cheng LJ, Ho YP, Tzeng SF, Chang MH, Hong JS. Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection. Neuroreport 2002, 13:277-280. 10.1097/00001756-200203040-00006, 11930122.
9. Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, Bing G. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 2009, 87:1913-1921. 10.1002/jnr.22012, 2692550, 19224579.
10. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR, Hardy R, Lewis G, Mason JM. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000, 4:CD002791.
11. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat Rev Neurol 2012, 8:35-47.
12. Ceravolo R, Nuti A, Piccinni A, Dell'Agnello G, Bellini G, Gambaccini G, Dell'Osso L, Murri L, Bonuccelli U. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000, 55:1216-1218. 10.1212/WNL.55.8.1216, 11071504.
13. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000, 15:986-989. 10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I, 11009210.
14. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010, 185:1230-1237. 10.4049/jimmunol.1000208, 20566832.
15. Song X, Shapiro S, Goldman DL, Casadevall A, Scharff M, Lee SC. Fcgamma receptor I- and III-mediated macrophage inflammatory protein 1alpha induction in primary human and murine microglia. Infect Immun 2002, 70:5177-5184. 10.1128/IAI.70.9.5177-5184.2002, 128255, 12183568.
16. Zhu JH, Lei XG. Double null of selenium-glutathione peroxidase-1 and copper, zinc-superoxide dismutase enhances resistance of mouse primary hepatocytes to acetaminophen toxicity. Exp Biol Med (Maywood) 2006, 231:545-552.
17. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in vitro model of brain inflammation. J Neuroinflammation 2010, 7:30. 10.1186/1742-2094-7-30, 2880998, 20482831.
18. Zhu JH, Chen CL, Flavahan S, Harr J, Su B, Flavahan NA. Cyclic stretch stimulates vascular smooth muscle cell alignment by redox-dependent activation of Notch3. Am J Physiol Heart Circ Physiol 2011, 300:H1770-H1780. 10.1152/ajpheart.00535.2010, 3094076, 21169401.
19. Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 2004, 25:431-439. 10.1016/S0197-4580(03)00126-X, 15013563.
20. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005, 175:4320-4330.
21. Kaushal V, Schlichter LC. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008, 28:2221-2230.
22. Novarino G, Fabrizi C, Tonini R, Denti MA, Malchiodi-Albedi F, Lauro GM, Sacchetti B, Paradisi S, Ferroni A, Curmi PM, Breit SN, Mazzanti M. Involvement of the intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity. J Neurosci 2004, 24:5322-5330. 10.1523/JNEUROSCI.1170-04.2004, 15190104.
23. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978, 38:3751-3757.
24. Farooqui SM. Induction of adenylate cyclase sensitive dopamine D2-receptors in retinoic acid induced differentiated human neuroblastoma SHSY-5Y cells. Life Sci 1994, 55:1887-1893. 10.1016/0024-3205(94)00520-6, 7990648.
25. Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol 2009, 85:352-370.
26. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56. 10.1038/nrn2297, 2919277, 18073775.
27. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009, 33:355-366. 10.1016/j.neubiorev.2008.10.005, 18996146.
28. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479. 2987579, 21051678.
29. Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001, 63:221-224. 10.1016/S0165-0327(00)00164-6, 11246099.
30. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291. 10.1212/WNL.38.8.1285, 3399080.
31. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357-365. 10.1016/j.it.2008.05.002, 18599350.
32. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78:915-918. 10.1016/0092-8674(94)90266-6, 7522969.
33. Shen S, Yu S, Binek J, Chalimoniuk M, Zhang X, Lo SC, Hannink M, Wu J, Fritsche K, Donato R, Sun GY. Distinct signaling pathways for induction of type II NOS by IFNgamma and LPS in BV-2 microglial cells. Neurochem Int 2005, 47:298-307. 10.1016/j.neuint.2005.03.007, 15955597.
34. Moss DW, Bates TE. Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci 2001, 13:529-538. 10.1046/j.1460-9568.2001.01418.x, 11168560.
35. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424. 10.1152/physrev.00029.2006, 2248324, 17237348.
36. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012, 26:469-479. 10.1016/j.bbi.2011.12.011, 22251606.
37. Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss HJ, Laux G, Muller-Oerlinghausen B, Rao ML, Riederer P, Zernig G, Hiemke C. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 2005, 7:231-247. 3181735, 16156382.
38. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683. 10.1146/annurev.immunol.14.1.649, 8717528.
39. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011, 61:592-599. 10.1016/j.neuropharm.2011.04.033, 21575647.
40. Jung HW, Chung YS, Kim YS, Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 2007, 39:715-721. 10.1038/emm.2007.78, 18160842.
41. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KC. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002, 16:2103-2112. 10.1046/j.1460-9568.2002.02290.x, 12473078.
42. Hou RC, Chen HL, Tzen JT, Jeng KC. Effect of sesame antioxidants on LPS-induced NO production by BV2 microglial cells. Neuroreport 2003, 14:1815-1819. 10.1097/00001756-200310060-00011, 14534426.
43. Svensson C, Fernaeus SZ, Part K, Reis K, Land T. LPS-induced iNOS expression in Bv-2 cells is suppressed by an oxidative mechanism acting on the JNK pathway - a potential role for neuroprotection. Brain Res 2010, 1322:1-7.
44. Kacimi R, Giffard RG, Yenari MA. Endotoxin-activated microglia injure brain derived endothelial cells via NF-kappaB, JAK-STAT and JNK stress kinase pathways. J Inflamm 2011, 8:7.
45. Wen J, Ribeiro R, Zhang Y. Specific PKC isoforms regulate LPS-stimulated iNOS induction in murine microglial cells. J Neuroinflammation 2011, 8:38. 10.1186/1742-2094-8-38, 3110130, 21510893.
46. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24:27-53. 10.1007/s11011-008-9118-1, 19085093.